Aspen Aerogels Inc. (NYSE:ASPN) has earned an average recommendation of “Hold” from the eight ratings firms that are covering the company. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.60.

ASPN has been the topic of several analyst reports. JPMorgan Chase & Co. reduced their target price on shares of Aspen Aerogels from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. Zacks Investment Research raised shares of Aspen Aerogels from a “sell” rating to a “hold” rating in a report on Wednesday, October 5th. Seaport Global Securities cut shares of Aspen Aerogels from a “buy” rating to a “neutral” rating in a report on Friday, November 4th. Citigroup Inc. cut shares of Aspen Aerogels from a “buy” rating to a “neutral” rating and reduced their target price for the company from $6.00 to $4.50 in a report on Monday, November 14th. Finally, Craig Hallum started coverage on shares of Aspen Aerogels in a research note on Tuesday, September 20th. They issued a “buy” rating and a $10.00 price target on the stock.

Aspen Aerogels (NYSE:ASPN) opened at 3.94 on Tuesday. Aspen Aerogels has a 12 month low of $3.38 and a 12 month high of $6.85. The stock has a 50 day moving average of $5.76 and a 200-day moving average of $4.98. The stock’s market cap is $81.09 million.

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Thursday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.04. The firm earned $29.60 million during the quarter, compared to analyst estimates of $29.05 million. Aspen Aerogels had a negative net margin of 3.64% and a negative return on equity of 3.82%. The firm’s revenue was down 6.0% compared to the same quarter last year. During the same period last year, the business earned ($0.11) EPS. On average, equities analysts forecast that Aspen Aerogels will post ($0.41) EPS for the current fiscal year.

In other Aspen Aerogels news, Director William P. Noglows bought 20,000 shares of the stock in a transaction dated Wednesday, August 24th. The shares were acquired at an average cost of $4.98 per share, for a total transaction of $99,600.00. Following the completion of the transaction, the director now owns 46,178 shares in the company, valued at approximately $229,966.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Reilly bought 10,000 shares of the stock in a transaction dated Tuesday, August 23rd. The shares were acquired at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the completion of the transaction, the director now owns 36,178 shares of the company’s stock, valued at approximately $174,377.96. The disclosure for this purchase can be found here. 14.70% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Balter Liquid Alternatives LLC raised its position in shares of Aspen Aerogels by 162.8% in the first quarter. Balter Liquid Alternatives LLC now owns 33,236 shares of the company’s stock worth $150,000 after buying an additional 20,590 shares during the period. Firsthand Capital Management Inc. raised its position in shares of Aspen Aerogels by 16.7% in the second quarter. Firsthand Capital Management Inc. now owns 35,000 shares of the company’s stock worth $174,000 after buying an additional 5,000 shares during the period. TD Asset Management Inc. raised its position in shares of Aspen Aerogels by 9.3% in the third quarter. TD Asset Management Inc. now owns 35,200 shares of the company’s stock worth $210,000 after buying an additional 3,000 shares during the period. Mesirow Financial Investment Management Equity Management acquired a new position in shares of Aspen Aerogels during the third quarter worth about $216,000. Finally, RBF Capital LLC raised its position in shares of Aspen Aerogels by 14.2% in the third quarter. RBF Capital LLC now owns 41,111 shares of the company’s stock worth $245,000 after buying an additional 5,100 shares during the period. Institutional investors and hedge funds own 79.09% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Receive News & Stock Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related stocks with our FREE daily email newsletter.